Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,231,775 papers from all fields of science
Search
Sign In
Create Free Account
Anti-CTLA-4 Monoclonal Antibody AGEN1884
Known as:
AGEN-1884
, AGEN1884
A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
CTLA4 protein, human
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
V. Florou
,
A. Rosenberg
,
+7 authors
B. Wilky
Journal of Immunotherapy for Cancer
2019
Corpus ID: 199486225
BackgroundAngiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative…
Expand
2018
2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
R. Gombos
,
Ana González
,
+24 authors
N. Wilson
PloS one
2018
Corpus ID: 4824675
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen…
Expand
Review
2018
Review
2018
Evaluation of Peripheral T-Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors
P. DeSouza
,
E. Drouin
2018
Corpus ID: 51777556
• Antigen-speci c T-cell activation is regulated by a balance of co-stimulatory and co-inhibitory signals, such as those mediated…
Expand
2018
2018
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
B. Wilky
,
P. Kumthekar
,
+16 authors
R. Stein
2018
Corpus ID: 81419804
3075Background: AGEN1884 is a novel fully human IgG1 monoclonal antibody targeting cytotoxic T lymphocyte-associated protein 4…
Expand
2018
2018
Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors.
J. Coward
,
C. Lemech
,
+12 authors
H. Youssoufian
Annals of oncology : official journal of the…
2018
Corpus ID: 81576557
2018
2018
Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy.
B. Wilky
,
P. Kumthekar
,
+17 authors
H. Youssoufian
Annals of oncology : official journal of the…
2018
Corpus ID: 81670250
2017
2017
Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.
B. Wilky
,
P. Kumthekar
,
+11 authors
J. Cuillerot
2017
Corpus ID: 80328802
3075Background: AGEN1884 is a fully human IgG1 monoclonal antibody targeting the co-inhibitory protein cytotoxic T lymphocyte…
Expand
2017
2017
Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model
Elise E. Drouin
,
D. Savitsky
,
+19 authors
N. Wilson
2017
Corpus ID: 89825813
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) play important non-redundant…
Expand
2016
2016
Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies
Elise E. Drouin
,
Ana González
,
+18 authors
N. Wilson
2016
Corpus ID: 88758625
CTLA-4 is an important negative regulator of T cell function. Together with CD28, these two co-receptors exemplify a co…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE